Teva Pharmaceutical Stock Could Double | Barron's
Teva to acquire Mexico's Rimsa for $2.3 billion - MarketWatch
Teva stock drops on guidance, manufacturing problems - MarketWatch
Teva's generic EpiPen approved in the U.S., with perfect timing - MarketWatch
Teva Pharmaeutical Stock Gets Upgrade From Analyst | Barron's
Teva Pharmaceuticals (@TevaUSA) / Twitter
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Drug maker Teva's U.S. unit indicted on price-fixing charges - MarketWatch
Teva Stock Climbs as Earnings Hint at Turnaround | Barron's
Teva stock drops on guidance, manufacturing problems - MarketWatch
Teva Pharmaceutical Names Richard Francis as CEO, President - WSJ
TEVA | Teva Pharmaceutical Industries Ltd. ADR Stock Overview (U.S.: NYSE) | Barron's
Teva Pharmaceuticals - Wikipedia
Teva Pharmaceuticals reports earnings on Wednesday. Here's what to expect - MarketWatch
Drug Stock Due for Another Climb on the Charts
Teva Stock Jumps Following Tentative Deal to Settle Opioid Cases | Barron's
Prosecutors Sue Teva's U.S. Business Over Charitable Donations - WSJ
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Announces Abstracts at the ACAAI Annual Scientific Meeting
What To Do After TEVA Stock Falls Below $10 Again (NYSE:TEVA) | Seeking Alpha
Teva Tries to Put an End to the Opioid Wars - WSJ
Teva shares drop 3% after rival generic product approved and launched - MarketWatch
Teva - Updates, News, Events, Signals & Triggers
Israel stocks rise, led by Teva, ICL - MarketWatch
Teva Stock Is Falling as an Analyst Says It Needs 'Numerous Litigation Wins' | Barron's
